# Phenobarbital
*Source: https://go.drugbank.com/drugs/DB01174*

## Overview

### Description

This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.

### Background

A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.

### Indication

For the treatment of all types of seizures except absence seizures.

### Pharmacodynamics

Phenobarbital, the longest-acting barbiturate, is used for its anticonvulsant and sedative-hypnotic properties in the management of all seizure disorders except absence (petit mal).

### Mechanism of Action

Gamma-aminobutyric acid receptor subunit alpha-1
Potentiator

### Absorption

Absorbed in varying degrees following oral, rectal or parenteral administration. The salts are more rapidly absorbed than are the acids. The rate of absorption is increased if the sodium salt is ingested as a dilute solution or taken on an empty stomach.

### Metabolism

Hepatic (mostly via CYP2C19).
Hover over products below to view reaction partners
Phenobarbital
p-Hydroxyphenobarbital
Phenobarbital O-glucuronide
Phenobarbital O-sulfate

### Half-life

53 to 118 hours (mean 79 hours)

### Toxicity

CNS and respiratory depression which may progress to Cheyne-Stokes respiration, areflexia, constriction of the pupils to a slight degree (though in severe poisoning they may wshow paralytic dilation), oliguria, tachycardia, hypotension, lowered body temperature, and coma. Typical shock syndrome (apnea, circulatory collapse, respiratory arrest, and death) may occur.

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The metabolism of 1,2-Benzodiazepine can be increased when combined with Phenobarbital.
Abacavir
The metabolism of Abacavir can be increased when combined with Phenobarbital.
Abaloparatide
Phenobarbital may increase the hypotensive activities of Abaloparatide.
Abatacept
The metabolism of Phenobarbital can be increased when combined with Abatacept.
Abemaciclib
The metabolism of Abemaciclib can be increased when combined with Phenobarbital.

### Food Interactions

Administer vitamin supplements.
Avoid alcohol.
Limit caffeine intake.
Take on an empty stomach. Taking this medication on an empty stomach increases the speed of absorption.

## Chemical Information

**DrugBank ID:** DB01174

**Synonyms:** 5-ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Ethyl-5-phenyl-pyrimidine-2,4,6-trione
5-Ethyl-5-phenylbarbituric acid
5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione
5-Phenyl-5-ethylbarbituric acid
Fenobarbital
Phenobarbital
Phenobarbitol
Phenobarbitone
Phenobarbituric Acid
Phenyläthylbarbitursäure
Phenylethylbarbiturate
Phenylethylbarbituric Acid
Phenylethylbarbitursäure
Phenylethylmalonylurea

**Chemical Formula:** C
12
H
12
N
2
O
3

**SMILES:** CCC1(C(=O)NC(=O)NC1=O)C1=CC=CC=C1

**Weight:** Average: 232.2353
Monoisotopic: 232.08479226

**IUPAC Name:** 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione

## Additional Information

### Modality

Small Molecule

### Patents

Patent Number
Pediatric Extension
Expires (estimated)
Region
US11857683
No
2024-01-02
2042-04-07
US

### Indicated Conditions

9

### Phase 0

0

### Phase 1

3

### Phase 2

6

### Phase 3

11

### Phase 4

8

### Therapeutic Categories

Barbiturates

### Summary

Phenobarbital
is a long-lasting barbiturate and anticonvulsant used in the treatment of all types of seizures, except for absent seizures.

### Brand Names

Donnatal, Luminal, Phenobarb, Phenohytro, Sezaby

### Generic Name

Phenobarbital

### DrugBank Accession Number

DB01174

### Groups

Approved, Investigational

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Phenobarbital (DB01174)
×
Close

### External IDs

NSC-128143
NSC-9848

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Symptomatic treatment of
Alcohol withdrawal
••• •••••
Create Account
Treatment of
Anxiety
••••••••••••
Create Account
Treatment of
Febrile seizures
••••••••••••
Create Account
Prophylaxis of
Febrile seizures
••••••••••••
Create Account
Treatment of
Hyperbilirubinemia
••••••••••••
Create Account
Create Account

### Associated Therapies

Sedation

### Mechanism of action

Phenobarbital acts on GABAA receptors, increasing synaptic inhibition. This has the effect of elevating seizure threshold and reducing the spread of seizure activity from a seizure focus. Phenobarbital may also inhibit calcium channels, resulting in a decrease in excitatory transmitter release. The sedative-hypnotic effects of phenobarbital are likely the result of its effect on the polysynaptic midbrain reticular formation, which controls CNS arousal.
Target
Actions
Organism
A
Gamma-aminobutyric acid receptor subunit alpha-1
potentiator
Humans
U
Neuronal acetylcholine receptor subunit alpha-4
antagonist
Humans
U
Neuronal acetylcholine receptor subunit alpha-7
antagonist
Humans
U
Glutamate receptor 2
antagonist
Humans
U
Glutamate receptor ionotropic, kainate 2
antagonist
Humans
U
NMDA receptor
antagonist
Humans
U
Nuclear receptor subfamily 1 group I member 2
activator
Humans

### Protein binding

20 to 45%

### Product Ingredients

Ingredient
UNII
CAS
InChI Key
Phenobarbital sodium
SW9M9BB5K3
57-30-7
WRLGYAWRGXKSKG-UHFFFAOYSA-M

### Product Images

Previous
Next

### International/Other Brands

Luminal

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Phenobarbital
Tablet
32.4 mg/1
Oral
E5 Pharma, Llc
2017-02-24
2025-11-09
US
Phenobarbital
Liquid
20 mg/5mL
Oral
bryant ranch prepack
2020-09-01
Not applicable
US
Phenobarbital
Tablet
16.2 mg/1
Oral
QUAGEN PHARMACEUTICALS LLC
2020-09-15
Not applicable
US
Phenobarbital
Tablet
100 mg/1
Oral
Genus Lifesciences Inc.
2025-03-01
Not applicable
US
Phenobarbital
Tablet
32.4 mg/1
Oral
Sterling-Knight Pharmaceuticals, LLC
2017-03-28
Not applicable
US

### Mixture Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
Bellergal Spacetabs
Phenobarbital
(40.0 mg)
+
Belladonna
(0.2 mg)
+
Ergotamine tartrate
(0.6 mg)
Tablet, extended release
Oral
Paladin Pharma Inc.
1959-01-01
2018-06-05
Canada
Bellergal Tab
Phenobarbital
(20 mg / tab)
+
Belladonna
(.1 mg / tab)
+
Ergotamine tartrate
(.3 mg / tab)
Tablet
Oral
Sandoz S.P.A.
1951-12-31
1997-08-12
Canada
Diclophen
Phenobarbital
(15 mg)
+
Dicyclomine hydrochloride
(10 mg)
Capsule
Oral
Pro Doc Limitee
1970-12-31
2009-07-23
Canada
Dilantin W Phenobarbital 15mg
Phenobarbital
(15 mg / cap)
+
Phenytoin sodium
(100 mg / cap)
Capsule
Oral
Parke Davis Division, Warner Lambert Canada Inc.
1951-12-31
1999-04-08
Canada
Dilantin W Phenobarbital 30mg Cap
Phenobarbital
(30 mg / cap)
+
Phenytoin sodium
(100 mg / cap)
Capsule
Oral
Parke Davis Division, Warner Lambert Canada Inc.
1969-12-31
1997-08-25
Canada

### Unapproved/Other Products

Name
Ingredients
Dosage
Route
Labeller
Marketing Start
Marketing End
Region
Image
B-Donna
Phenobarbital
(16.2 mg/1)
+
Atropine sulfate
(0.0194 mg/1)
+
Hyoscyamine sulfate dihydrate
(0.1037 mg/1)
+
Scopolamine
(0.0065 mg/1)
Tablet
Oral
Winder Laboratories, LLC
2015-12-30
2016-03-03
US
Belladonna Alkaloids with Phenobarbital
Phenobarbital
(16.2 mg/1)
+
Atropine sulfate
(0.0194 mg/1)
+
Hyoscyamine sulfate dihydrate
(0.1037 mg/1)
+
Scopolamine
(0.0065 mg/1)
Tablet
Oral
Hikma Pharmaceuticals USA Inc.
1966-01-01
2019-07-31
US
Belladonna Alkaloids with Phenobarbital
Phenobarbital
(16.2 mg/1)
+
Atropine sulfate
(0.0194 mg/1)
+
Hyoscyamine sulfate dihydrate
(0.1037 mg/1)
+
Scopolamine
(0.0065 mg/1)
Tablet
Oral
bryant ranch prepack
1966-01-01
2015-05-01
US
Belladonna Alkaloids with Phenobartbital
Phenobarbital
(16.2 mg/1)
+
Atropine sulfate
(0.0194 mg/1)
+
Hyoscyamine sulfate dihydrate
(0.1037 mg/1)
+
Scopolamine
(0.0065 mg/1)
Tablet
Oral
Liberty Pharmaceuticals, Inc.
2000-12-01
Not applicable
US
Belladonna Alkaloids with Phenobartbital
Phenobarbital
(16.2 mg/1)
+
Atropine sulfate
(0.0194 mg/1)
+
Hyoscyamine sulfate dihydrate
(0.1037 mg/1)
+
Scopolamine
(0.0065 mg/1)
Tablet
Oral
Physicians Total Care, Inc.
2004-08-31
2013-01-15
US

### ATC Codes

N05CB01 — Combinations of barbiturates
N05CB — Barbiturates, combinations
N05C — HYPNOTICS AND SEDATIVES
N05 — PSYCHOLEPTICS
N — NERVOUS SYSTEM
N03AA02 — Phenobarbital
N03AA — Barbiturates and derivatives
N03A — ANTIEPILEPTICS
N03 — ANTIEPILEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Anticholinergic Agents
Anticonvulsants
Barbiturates
Barbiturates and Derivatives
BSEP/ABCB11 inducers
Central Nervous System Agents
Central Nervous System Depressants
Chemically-Induced Disorders
Cytochrome P-450 CYP1A2 Inducers
Cytochrome P-450 CYP1A2 Inducers (strength unknown)
Cytochrome P-450 CYP2A6 Inducers
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 CYP2B6 Inducers (strong)
Cytochrome P-450 CYP2C18 Substrates
Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index
Cytochrome P-450 CYP2C19 Inducers
Cytochrome P-450 CYP2C19 Inducers (strength unknown)
Cytochrome P-450 CYP2C19 Substrates
Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index
Cytochrome P-450 CYP2C8 Inducers
Cytochrome P-450 CYP2C8 Inducers (strength unknown)
Cytochrome P-450 CYP2C9 Inducers
Cytochrome P-450 CYP2C9 Inducers (strength unknown)
Cytochrome P-450 CYP2C9 Substrates
Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index
Cytochrome P-450 CYP2E1 Inducers
Cytochrome P-450 CYP2E1 Inducers (strength unknown)
Cytochrome P-450 CYP2E1 Inducers (weak)
Cytochrome P-450 CYP2E1 Substrates
Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 CYP3A Inducers (strong)
Cytochrome P-450 CYP3A4 Inducers
Cytochrome P-450 CYP3A4 Inducers (strong)
Cytochrome P-450 CYP3A5 Inducers
Cytochrome P-450 CYP3A5 Inducers (strong)
Cytochrome P-450 CYP3A7 Inducers
Cytochrome P-450 CYP3A7 Inducers (strength unknown)
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 Substrates
Enzyme Inducing Antiepileptic Drugs
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
GABA Agents
GABA Modulators
Hypnotics and Sedatives
Methemoglobinemia Associated Agents
Narrow Therapeutic Index Drugs
Nervous System
Neurotransmitter Agents
Nicotinic Antagonists
P-glycoprotein inducers
P-glycoprotein substrates
P-glycoprotein substrates with a Narrow Therapeutic Index
Phenobarbital and similars
Psycholeptics
Pyrimidines
Pyrimidinones
UGT1A1 Inducers
UGT2B7 inducers

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Barbituric acid derivatives
Alternative Parents
N-acyl ureas
/
Diazinanes
/
Benzene and substituted derivatives
/
Dicarboximides
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organonitrogen compounds
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
Substituents
1,3-diazinane
/
Aromatic heteromonocyclic compound
/
Azacycle
/
Barbiturate
/
Benzenoid
/
Carbonic acid derivative
/
Carbonyl group
/
Carboxylic acid derivative
/
Dicarboximide
/
Hydrocarbon derivative
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
barbiturates (
CHEBI:8069
)

### Kingdom

Organic compounds

### Super Class

Organoheterocyclic compounds

### Class

Diazines

### Sub Class

Pyrimidines and pyrimidine derivatives

### Direct Parent

Barbituric acid derivatives

### Alternative Parents

N-acyl ureas
/
Diazinanes
/
Benzene and substituted derivatives
/
Dicarboximides
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organonitrogen compounds
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds

### Substituents

1,3-diazinane
/
Aromatic heteromonocyclic compound
/
Azacycle
/
Barbiturate
/
Benzenoid
/
Carbonic acid derivative
/
Carbonyl group
/
Carboxylic acid derivative
/
Dicarboximide
/
Hydrocarbon derivative

### Molecular Framework

Aromatic heteromonocyclic compounds

### External Descriptors

barbiturates (
CHEBI:8069
)

### Affected organisms

Humans and other mammals

### UNII

YQE403BP4D

### CAS number

50-06-6

### InChI Key

DDBREPKUVSBGFI-UHFFFAOYSA-N

### InChI

InChI=1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)

### Synthesis Reference

Tong Sun, Shawn Watson, Rajesh Manchanda, "PHENOBARBITAL SALTS; METHODS OF MAKING; AND METHODS OF USE THEREOF." U.S. Patent US20100035904, issued February 11, 2010.
US20100035904

### General References

Kwan P, Brodie MJ: Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia. 2004 Sep;45(9):1141-9. [
Article
]
Taylor S, Tudur Smith C, Williamson PR, Marson AG: Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalized onset tonic-clonic seizures. Cochrane Database Syst Rev. 2001;(4):CD002217. [
Article
]
Tudur Smith C, Marson AG, Williamson PR: Carbamazepine versus phenobarbitone monotherapy for epilepsy. Cochrane Database Syst Rev. 2003;(1):CD001904. [
Article
]
Kalviainen R, Eriksson K, Parviainen I: Refractory generalised convulsive status epilepticus : a guide to treatment. CNS Drugs. 2005;19(9):759-68. [
Article
]
Booth D, Evans DJ: Anticonvulsants for neonates with seizures. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004218. [
Article
]
Pacifici GM: Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics. Curr Pediatr Rev. 2016;12(1):48-54. doi: 10.2174/1573397111666151026223914. [
Article
]

### External Links

Human Metabolome Database
HMDB0015305
KEGG Drug
D00506
KEGG Compound
C07434
PubChem Compound
4763
PubChem Substance
46505776
ChemSpider
4599
BindingDB
50021437
RxNav
8134
ChEBI
8069
ChEMBL
CHEMBL40
ZINC
ZINC000095588079
Therapeutic Targets Database
DAP000061
PharmGKB
PA450911
Guide to Pharmacology
GtP Drug Page
PDBe Ligand
UQA
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Phenobarbital

### Human Metabolome Database

HMDB0015305

### KEGG Drug

D00506

### KEGG Compound

C07434

### PubChem Compound

4763

### PubChem Substance

46505776

### ChemSpider

4599

### BindingDB

50021437

### RxNav

8134

### ChEBI

8069

### ChEMBL

CHEMBL40

### ZINC

ZINC000095588079

### Therapeutic Targets Database

DAP000061

### PharmGKB

PA450911

### Guide to Pharmacology

GtP Drug Page

### PDBe Ligand

UQA

### RxList

RxList Drug Page

### Drugs.com

Drugs.com Drug Page

### PDRhealth

PDRhealth Drug Page

### Wikipedia

Phenobarbital

### PDB Entries

6x3w

### MSDS

Download
(53 KB)

### Packagers

Actavis Group
Amend
Apotheca Inc.
Baxter International Inc.
Breckenridge Pharmaceuticals
C.O. Truxton Inc.
Cardinal Health
Carlisle Laboratories Inc.
Century Pharmaceuticals Inc.
Comprehensive Consultant Services Inc.
Direct Dispensing Inc.
Dispensing Solutions
Diversified Healthcare Services Inc.
Econolab Inc.
Excellium Pharmaceutical Inc.
Group Health Cooperative
Heartland Repack Services LLC
Hikma Pharmaceuticals
Hl Moore Drug Exchange
Hospira Inc.
Kaiser Foundation Hospital
Kraft Pharmaceutical Co. Inc.
Lake Erie Medical and Surgical Supply
Lundbeck Inc.
Major Pharmaceuticals
Mallinckrodt Inc.
Mckesson Corp.
Murfreesboro Pharmaceutical Nursing Supply
Nucare Pharmaceuticals Inc.
Ohm Laboratories Inc.
PD-Rx Pharmaceuticals Inc.
Pharmaceutical Association
Pharmaceutical Utilization Management Program VA Inc.
Pharmacy Service Center
Pharmedix
Physicians Total Care Inc.
Preferred Pharmaceuticals Inc.
Prepak Systems Inc.
Qualitest
Ranbaxy Laboratories
Remedy Repack
Resource Optimization and Innovation LLC
River's Edge Pharmaceuticals
Stanley Pharmaceuticals Ltd.
UDL Laboratories
United Research Laboratories Inc.
Vintage Pharmaceuticals Inc.
West-Ward Pharmaceuticals

### Dosage Forms

Form
Route
Strength
Elixir
Oral
4 mg / mL
Tablet, extended release
Oral
Tablet, film coated, extended release
Oral
Tablet
Oral
100.000 mg
Solution
Oral
400 mg
Tablet
Oral
10 mg
Solution
Intramuscular; Intravenous
0.2 g
Solution
Parenteral
200 mg
Injection
Parenteral
40 mg
Tablet
Oral
100 mg
Tablet
Oral
50 mg
Injection, solution
Parenteral
100 MG/ML
Injection, solution
Intramuscular
100 MG/2ML
Injection, solution
Intramuscular
30 MG/ML
Solution
Intramuscular; Intravenous
40 mg
Injection, solution
Intramuscular
100 MG
Elixir
Oral
0.3 %
Injection, solution
Intramuscular; Parenteral
200 MG/ML
Syrup
50 MG/10ML
Capsule
Oral
Tablet
Oral
15 mg
Tablet
Oral
30 mg
Tablet
Oral
60 mg
Solution
Oral
5 mg / mL
Elixir
Oral
20 mg/5mL
Elixir
Oral
20.0 mg/5mL
Liquid
Oral
20 mg/5mL
Solution
Oral
20 mg/5mL
Tablet
Oral
Tablet
Oral
100 mg/1
Tablet
Oral
15 mg/1
Tablet
Oral
16.2 mg/1
Tablet
Oral
30 mg/1
Tablet
Oral
32.4 mg/1
Tablet
Oral
60 mg/1
Tablet
Oral
64.8 mg/1
Tablet
Oral
97.2 mg/1
Solution
Oral
30 mg/7.5mL
Solution
Oral
60 mg/15mL
Injection
Intramuscular
130 mg/1mL
Injection
Intramuscular
65 mg/1mL
Injection
Intramuscular; Intravenous
130 mg/1mL
Injection
Intramuscular; Intravenous
65 mg/1mL
Injection
Parenteral
50 MG/ML
Injection, solution
Intramuscular; Intravenous
130 mg/1mL
Injection, solution
Intramuscular; Intravenous
65 mg/1mL
Solution
Intramuscular; Intravenous; Subcutaneous
30 mg / mL
Solution
Intramuscular; Intravenous
120 mg / mL
Solution
Intramuscular; Intravenous
30 mg / mL
Elixir
Oral
Tablet
Oral
Injection
Parenteral
100 MG/ML
Suppository
Rectal
Injection
Intravenous
100 mg/1
Liquid
Oral

### Prices

Unit description
Cost
Unit
Phenobarbital 130 mg/ml vial
4.32USD
ml
Phenobarbital 65 mg/ml vial
1.63USD
ml
Phenobarbital sodium powder
0.36USD
g
Pms-Phenobarbital 100 mg Tablet
0.15USD
tablet
Phenobarbital powder
0.13USD
g
Pms-Phenobarbital 60 mg Tablet
0.11USD
tablet
Phenobarbital 97.2 mg tablet
0.1USD
tablet
Phenobarbital 64.8 mg tablet
0.09USD
tablet
Pms-Phenobarbital 5 mg/ml Elixir
0.09USD
ml
Phenobarbital 16.2 mg tablet
0.08USD
tablet
Phenobarbital 30 mg tablet
0.08USD
tablet
Phenobarbital 32.4 mg tablet
0.08USD
tablet
Pms-Phenobarbital 30 mg Tablet
0.08USD
tablet
Phenobarbital 100 mg tablet
0.07USD
tablet
Pms-Phenobarbital 15 mg Tablet
0.07USD
tablet
PHENobarbital 20 mg/5ml Elixir
0.06USD
ml
Phenobarbital 60 mg tablet
0.03USD
tablet
Phenobarbital 15 mg tablet
0.02USD
tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Solid

### Experimental Properties

Property
Value
Source
melting point (°C)
174 °C
PhysProp
water solubility
1110 mg/L (at 25 °C)
YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP
1.47
HANSCH,C ET AL. (1995)
pKa
7.3
BUDAVARI,S ET AL. (1996)

### Predicted Properties

Property
Value
Source
Water Solubility
0.276 mg/mL
ALOGPS
logP
1.4
ALOGPS
logP
1.41
Chemaxon
logS
-2.9
ALOGPS
pKa (Strongest Acidic)
7.14
Chemaxon
Physiological Charge
-1
Chemaxon
Hydrogen Acceptor Count
3
Chemaxon
Hydrogen Donor Count
2
Chemaxon
Polar Surface Area
75.27 Å
2
Chemaxon
Rotatable Bond Count
2
Chemaxon
Refractivity
59.75 m
3
·mol
-1
Chemaxon
Polarizability
22.59 Å
3
Chemaxon
Number of Rings
2
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9935
Blood Brain Barrier
+
0.9736
Caco-2 permeable
-
0.5561
P-glycoprotein substrate
Substrate
0.5157
P-glycoprotein inhibitor I
Non-inhibitor
0.6472
P-glycoprotein inhibitor II
Non-inhibitor
0.9869
Renal organic cation transporter
Non-inhibitor
0.9235
CYP450 2C9 substrate
Non-substrate
0.6962
CYP450 2D6 substrate
Non-substrate
0.9116
CYP450 3A4 substrate
Non-substrate
0.7702
CYP450 1A2 substrate
Non-inhibitor
0.84
CYP450 2C9 inhibitor
Non-inhibitor
0.9023
CYP450 2D6 inhibitor
Non-inhibitor
0.9593
CYP450 2C19 inhibitor
Non-inhibitor
0.8664
CYP450 3A4 inhibitor
Non-inhibitor
0.9236
CYP450 inhibitory promiscuity
Low CYP Inhibitory Promiscuity
0.9164
Ames test
AMES toxic
0.9107
Carcinogenicity
Non-carcinogens
0.7469
Biodegradation
Not ready biodegradable
0.9894
Rat acute toxicity
3.1244 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.99
hERG inhibition (predictor II)
Non-inhibitor
0.9354
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Mass Spec (NIST)

Download
(8.44 KB)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-014i-1940000000-8377cca722b6479ce2fd
GC-MS Spectrum - EI-B
GC-MS
splash10-0udi-5970000000-7bda34bd3bb88b5fd9fd
GC-MS Spectrum - CI-B
GC-MS
splash10-001i-0090000000-55265fc1e12027dc6454
Mass Spectrum (Electron Ionization)
MS
splash10-0uxr-6950000000-193bf296d3e5d1705628
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-001i-0190000000-8cf53cd66a890256ea98
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-001i-1290000000-73d0e0b25f99ffc6a500
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-0016-3950000000-ab62a9483b8a2a65b563
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-0006-0900000000-4121e8dd703c01c1161c
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-0006-0900000000-4976dfc244184e5d627b
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-001i-1890000000-a12eb2be0b05b9f234de
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-03di-1920000000-43ed71cd16bfceef49e6
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-08fr-2900000000-236ae1dab83b15539a86
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-053u-3900000000-2a994f0e45c022cca640
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-053u-4900000000-066a53ca113150f58406
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-05o3-6900000000-b8f9c9d0f71b6d2c6c2f
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-0uy3-8900000000-6bcd457bfff85f05fe9c
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-0udi-9500000000-0ecfff7e43e9e78d677e
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-0uxs-9300000000-7413ad1c764a1ae4a98e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-001i-0390000000-f2147d068e18223694c5
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9310000000-8f28ab4d44583146115c
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-1900000000-3ee2f0a4c65cdb33c0aa
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9000000000-b05d6bfef8dfbacd745d
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-3940000000-bf59676229ff02f2fa16
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9120000000-73e8d9efbc75ac46d257
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-001i-0390000000-b80fd29f5e672b9a3083
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9210000000-8bc75358f3b56e3c0432
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-1900000000-96f4625a08add32dcca1
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9000000000-fd502df51e9ef52baa4e
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-0006-9110000000-9ea8c84e4188051e5b81
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-1930000000-c4d9938ef20de9f70a0d
1H NMR Spectrum
1D NMR
Not Applicable
13C NMR Spectrum
1D NMR
Not Applicable
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
157.4845834
predicted
DarkChem Lite v0.1.0
[M-H]-
159.3932
predicted
DeepCCS 1.0 (2019)
[M-H]-
157.4845834
predicted
DarkChem Lite v0.1.0
[M-H]-
159.3932
predicted
DeepCCS 1.0 (2019)
[M+H]+
158.2351834
predicted
DarkChem Lite v0.1.0
[M+H]+
161.75119
predicted
DeepCCS 1.0 (2019)
[M+H]+
158.2351834
predicted
DarkChem Lite v0.1.0
[M+H]+
161.75119
predicted
DeepCCS 1.0 (2019)
[M+Na]+
157.8849834
predicted
DarkChem Lite v0.1.0
[M+Na]+
167.84435
predicted
DeepCCS 1.0 (2019)
[M+Na]+
157.8849834
predicted
DarkChem Lite v0.1.0
[M+Na]+
167.84435
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Inducer

### General Function

ATP-dependent transporter of the ATP-binding cassette (ABC) family that binds and hydrolyzes ATP to enable active transport of various substrates including many drugs, toxicants and endogenous compound across cell membranes. Transports a wide variety of conjugated organic anions such as sulfate-, glucuronide- and glutathione (GSH)-conjugates of endo- and xenobiotics substrates (PubMed:10220572, PubMed:10421658, PubMed:11500505, PubMed:16332456). Mediates hepatobiliary excretion of mono- and bis-glucuronidated bilirubin molecules and therefore play an important role in bilirubin detoxification (PubMed:10421658). Also mediates hepatobiliary excretion of others glucuronide conjugates such as 17beta-estradiol 17-glucosiduronic acid and leukotriene C4 (PubMed:11500505). Transports sulfated bile salt such as taurolithocholate sulfate (PubMed:16332456). Transports various anticancer drugs, such as anthracycline, vinca alkaloid and methotrexate and HIV-drugs such as protease inhibitors (PubMed:10220572, PubMed:11500505, PubMed:12441801). Confers resistance to several anti-cancer drugs including cisplatin, doxorubicin, epirubicin, methotrexate, etoposide and vincristine (PubMed:10220572, PubMed:11500505)

### Specific Function

ABC-type glutathione S-conjugate transporter activity

### Gene Name

ABCC2

### Uniprot ID

Q92887

### Uniprot Name

ATP-binding cassette sub-family C member 2

### Molecular Weight

174205.64 Da

### Curator comments

Enzyme action based on in vivo study in rats. Only one study supports this currently.

